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Indwelling medical devices have become a major source of nosocomial infections; 21 
especially Pseudomonas aeruginosa (P. aeruginosa) infection, which remain the most 22 
common cause of ventilator associated pneumonia (VAP) in neonates and children.  Using 23 
medical grade polyvinyl chloride endotracheal tubes (ETTs), the activity of tobramycin and 24 
polymyxin-E was quantified in a simulated prevention and treatment static time kill model 25 
using biofilm forming P. aeruginosa.  The model simulated three clinical conditions: 1) 26 
planktonic bacteria in the presence of antibiotics, tobramycin and polymyxin-E, without 27 
ETTs, 2) planktonic bacteria grown in the presence of P. aeruginosa, antibiotic and ETTs 28 
(simulating prevention) and 3) a 24h formed P. aeruginosa biofilm on ETTs prior to 29 
antibiotic exposure (simulating treatment).  In the model simulating “prevention” 30 
(conditions 1 and 2 above), tobramycin alone or in combination with polymyxin-E was 31 
more bactericidal than polymyxin-E alone at 24 hours using a concentration greater than 2 32 
times the minimum inhibitory concentration (MIC).  However, after a 24h old biofilm was 33 
allowed to form on the ETTs, neither monotherapy nor combination therapy over 24 hours 34 
exhibited bactericidal or bacteriostatic effects.  Against the same pathogens, tobramycin 35 
and polymyxin-E, both alone or in combination exhibited bactericidal activity prior to 36 
biofilm attachment to the ETTs, however no activity was observed once biofilm formed on 37 
ETTs.  These findings support surveillance culturing to identify pathogens for a rapid and 38 
targeted approach to therapy, especially when P. aeruginosa is a potential pathogen. 39 




Indwelling medical devices are a major source of nosocomial infections.  In particular, 41 
patients requiring mechanical ventilation (intubation with an endotracheal tube (ETT)) face 42 
a high probability of contracting one of the most prevalent nosocomial infections, 43 
ventilator associated pneumonia (VAP).(1-3)  Neonatal and pediatric populations are at 44 
especially high risk for VAP because the current standard of care involves prolonged 45 
intubation without ETT exchange or tracheostomy, both common practice in adult patients.  46 
In neonates and infants, the inner diameter of the ETT is often 2.5-3.5mm (the size of a thin 47 
straw), which complicates suctioning of secretions and confounds attempts to maintain 48 
patency.  Despite aggressive bedside hygiene, Pseudomonas aeruginosa (P. aeruginosa) 49 
remains one of the most common causes of VAP in intubated children.(2, 4, 5)  50 
 51 
P. aeruginosa, often found on indwelling devices such as ETTs, forms a biofilm which 52 
serves as an ideal environment for antibiotic resistance, making VAP difficult to treat.(6, 7)  53 
Biofilm on ETTs is considered to be a reservoir for infecting pathogens derived from 54 
oropharyngeal flora and gastric microaspiration, and is highly correlated with lower airway 55 
infection and subsequent VAP.(8-11)  To date, few side-by-side studies have compared 56 
killing activity (defined as 99.9% kill) of tobramycin and polymyxin-E against P. 57 
aeruginosa, especially in the context of ETT biofilm and VAP.(12-15)  The effect of 58 
monotherapy and/or combination therapy (synergistic versus antagonistic activity) must be 59 
assessed when evaluating antimicrobial drug therapy, especially in the presence of medical 60 
grade polyvinyl chloride (PVC) or conventional ETTs.  For convenience, most studies 61 
investigating antibiotic susceptibility in formed biofilms have used PVC coupons rather 62 
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than clinically available medical devices.(16-18)  However, most of the coupons made of 63 
PVC are not medical grade and, in many cases, do not contain equivalent plasticizer 64 
content.  These differences result in different texture and flexibility between medical grade 65 
PVC products and PVC coupons used in biofilm experiments.  Using clinically available 66 
ETTs, this study aimed to both assess the efficacy of antibiotics against planktonic vs. 67 
biofilm formed P. aeruginosa, and to identify which antibiotic, alone or combination, 68 
demonstrates the best in vitro activity against P. aeruginosa in the context of VAP.  69 
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MATERIALS AND METHODS 70 
Bacterial Isolates. American Type Culture Collection (ATCC, Manassas, VA, USA) strain 71 
25668 was obtained.  Reference strain PAO1 was obtained from Dr. Thomas Murray, 72 
Frank H. Netter MD School of Medicine, Quinnipiac University, North Haven, CT.(19, 20)  73 
Prior to use, all bacteria were stored in tryptic soy broth (TSB; Difco laboratories, Sparks, 74 
MD) with 15% glycerol and frozen at -80 ºC.  Both strains are prolific biofilm 75 
producers.(21, 22) 76 
  77 
Antimicrobial Agents. Commercially available, chemical grade polymyxin-E (lot# 78 
081M1525V) powder and chemical grade tobramycin (lot# 090M1196V) powder was 79 
purchased from Sigma Aldrich (St. Louis, MO).  Tobramycin and polymyxin-E powder 80 
were stored at 4oC.  Both tobramycin and polymyxin-E were diluted in sterile water and a 81 
fresh stock was made each day, and prior to every experiment.  Tobramycin and 82 
polymyxin-E were tested at one, two, four and eight times their respective minimal 83 
inhibitory concentration (MIC) at 0, 4 and 24 hours after inoculation.(23)  Cation Adjusted 84 
Mueller-Hinton broth (CA-MHB, Difco Laboratories, Sparks, MD) supplemented with 25 85 
mg/L calcium, 12.5 mg/L magnesium and 0.25% dextrose (Fisher Scientific, Pittsburgh, 86 
PA, USA) was used to obtain a suspension corresponding to 0.7 - 0.8 McFarland standards 87 
to produce an initial starting inocula of 5.5-6.0 x 106 colony forming units per milliliter 88 
(CFU/mL).  Colony counts were determined using tryptic soy agar (TSA, Difco, Becton 89 
Dickinson Co., Sparks, MD) plates.   90 
 91 
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Susceptibility Testing. MIC tests were performed in triplicate using broth microdilution in 92 
accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines.(24, 25)  93 
The MIC was defined as the minimum concentration of antibiotic that will inhibit the 94 
visual growth of the isolated organism.  Minimum bactericidal concentrations (MBC) were 95 
also determined in triplicate for each antimicrobial agent using CSLI guidelines.(25)  96 
Bacteria were quantified using CFU/mL, and 5 microliter aliquots were used for 97 
determination of MBC after 24 hours incubation at 37oC using TSA.(26) 98 
 99 
Endotracheal Tubes (ETTs). Commercially available Sheridan® 6.0 mm ID, uncuffed 100 
ETTs (Hudson RIC, Temecula, CA, USA) were obtained.  Each ETT was cut into 0.6 cm 101 
by 0.3 cm rectangular pieces (ETT chips) using a ¼ rectangle hand puncher (Fiskars 102 
Corporation, Helsinki, Finland), and sterilized with ethylene oxide gas prior to use in pre-103 
formed and formed biofilm time kills experiments.(22)  For comparison, we also tested 104 
commercially available PVC coupons (part Number RD 128-PVC, Biosurface 105 
Technologies, Corp, Bozeman, MT) for pre-formed biofilm P. aeruginosa PAO1.(16-18) 106 
 107 
Biofilm Formation. Sterile ETT chips were placed in each well of a 24-well plate (BD 108 
Biosciences, San Jose, CA).  The ETT chip was submerged with 2 mL of a final bacteria 109 
inoculum, either PAO1 or ATCC 25668, obtained as described above using TSB 110 
supplemented with 1% dextrose, 2% NaCl and 25 mg/L calcium (STSB) using modified 111 
Growing and Analyzing Static Biofilms.(27)  The well plate was incubated at 37oC under 112 
static conditions for 24 hours to promote biofilm formation on ETT chips.  After 24 hours, 113 
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each ETT chip was gently rinsed three times in sterile phosphate buffered saline (PBS) 114 
(Fisher Scientific, Pittsburgh, PA). 115 
 116 
Time Kill Study. Using a 24h time kill study, three clinical conditions were modeled using 117 
P. aeruginosa strains PAO1 and 25668: 1) planktonic bacteria in the presence of the 118 
antibiotics tobramycin and polymyxin-E, without ETTs, 2) planktonic bacteria grown in 119 
the presence of P. aeruginosa, antibiotics and ETTs (simulating prevention) and 3) a 24h 120 
formed P. aeruginosa biofilm on ETTs prior to antibiotic exposure (simulating treatment).  121 
Each time kill experiment was carried out in a minimum of triplicate.  All antimicrobial 122 
agents were tested at one, two, four and eight times their respective MIC with starting 123 
inocula of 5.5–6.0 x 106 CFU/mL adjusted to McFarland standards using the Vitek 124 
colorimeter (bioMérieux, Inc, Durham, NC).(18, 28)  125 
 126 
Sample aliquots (0.1 mL) were removed from cultures at 0, 4, and 24 hours after vortexing 127 
each tube for one minute to remove biofilm growth from the ETT chip.(22)  Antimicrobial 128 
carryover was accounted for by serial dilution (10 – 10, 000 fold) of plated samples with 129 
normal saline or vacuum filtration.  This methodology has a lower limit of detection of 2.0 130 
log10 CFU/mL.(28)  Growth control tubes for each organism were prepared without 131 
antibiotic and run in parallel to the antibiotic test tubes.   132 
 133 
For single antimicrobial agents, bactericidal activity (99.9% kill) was defined as a ≥ 3 134 
log10CFU/mL reduction at 24h in colony count from the initial inoculum.  Bacteriostatic 135 
activity was defined as a < 3 log10 CFU/mL reduction at 24h in colony count from the 136 
   
8 
 
initial inoculum, while inactive was defined as no observed reduction from the initial 137 
inoculum.(23)  For antibiotics evaluated in combination, synergy was defined as ≥ 2 log10 138 
CFU/mL decrease, indifference was defined as a 1 to 2 log10 CFU/mL change (increase or 139 
decrease), and antagonism was defined as >2 log10 CFU/mL increase in growth compared 140 
to the most active single agent.    141 
 142 
Data analysis. All statistical analyses were performed using SPSS statistical software 143 
(IBM SPSS statistics version 20, IBM Corporation, Armonk, NY USA).  After 24 h of 144 
exposure to antimicrobial agent(s), the biofilm formation was quantified, bacteria at 4 hour 145 
and 24 hour were counted (with a lower limit of detection 2.0 log10 CFU/mL) to compare 146 
between antimicrobial groups, concentrations and strains using analysis of variance 147 
(ANOVA) followed by Tukey’s post-hoc analysis.  Multiple regressions for the association 148 
between substrates and CFU/mL were analyzed.  A p value of ≤ 0.05 indicated statistical 149 
significance.     150 




The MIC for tobramycin was 0.5 µg/mL and for polymyxin-E was 2 µg/mL for both PAO1 and 152 
25668 strains.  The MBC for tobramycin was 4 and 32 µg/mL and for polymyxin-E was 16 and 153 
64 µg/mL respectively for Pseudomonas PAO1 and ATCC 25668 strains.   154 
 155 
In the planktonic time kill study, tobramycin demonstrated bactericidal activity against both 156 
Pseudomonas isolates at 24 hours with average decrease of 3.81±0.16 log10 CFU/mL for all 157 
concentrations except 1 time the MIC for PAO1 (Fig. 1.a & b).  Polymyxin-E demonstrated 158 
bacteriostatic activity at 2 and 4 times the MIC (average decrease of 2.16-2.63 log10CFU/mL), 159 
and bactericidal activity at 8 times the MIC (average decrease of 3.07-3.56 log10CFU/mL), but 160 
inactive at 1 time the MIC for both isolates at 24 hours (Fig. 1.c & d).  The combination therapy 161 
at 2, 4, and 8 times the MIC demonstrated indifference with >3.44 log 10CFU/mL kill for PAO1, 162 
and >3.46 log 10CFU/mL kill for 25668 at 24 hours (Fig 1. e & f).   163 
 164 
In the pre-formed biofilm time kill studies (simulating prevention) at 24 hours, tobramycin 165 
demonstrated bactericidal activity against both Pseudomonas isolates (average decrease of > 3.3 166 
log 10CFU/mL), except 1 time the MIC for 25668 which showed inactivity (1.02±1.86 167 
log10CFU/mL increase; Fig 2.a & b).  Similarly, polymyxin-E demonstrated bactericidal activity 168 
(average decrease of >3.08 log 10CFU/mL) at greater than 2 times the MIC, but bacteriostatic 169 
activity at 1 time the MIC for both isolates at 24 hours (Fig. 2.c & d).  Tobramycin and 170 
polymyxin-E combination demonstrated indifferent activity at all concentrations for both isolates 171 
(Fig. 2.e & f).  172 
 173 
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In formed biofilm time kill studies (simulating treatment) for PAO1, combination therapy at 4 174 
times the MIC was significantly more active at 4 hours compared to polymyxin-E alone at 4 175 
times (mean difference (MD)= -1.34, 95% confidence interval [CI], -2.4-0.3 log 10 CFU/mL, p= 176 
0.004) and 8 times (MD= -1.45, 95% CI, -2.5-0.4 log 10 CFU/mL, p=0.001) the MIC.  Similarly, 177 
combination therapy at 8 times the MIC was significantly more active at 4 hours compared to 178 
polymyxin-E alone at 8 times the MIC (MD= -1.23, 95% CI, -2.3-0.2 log 10 CFU/mL, p=0.001).  179 
However, indifferent activity was observed at 24 hours.  Similarly, for 25668, combination 180 
therapy at 8 times the MIC was significantly more active compared to polymyxin-E alone at 4 181 
hours (MD= -1.06, 95% CI, -1.7-0.4 log 10 CFU/mL, p< 0.001).  However, indifferent activity 182 
was observed at 24 hours.  Once biofilm is formed, both single agent and combination antibiotics 183 
resulted in inactivity or indifference (Fig. 3. a - f).   184 
 185 
In addition to medical grade PVC ETTs, we assayed time kill using commercially available PVC 186 
coupons(16-18).  A similar trend of bactericidal activity was demonstrated at 24 hours with 187 
greater than 4 times the MIC of tobramycin (average decrease of >3.03 log10 CFU/mL) and with 188 
greater than 2 times the MIC of polymyxin-E (average decrease of >3.1 log10 CFU/mL), but 189 
indifference was noted when the combination of tobramycin and polymyxin-E was evaluated at 190 
2, 4, and 8 times the MIC (average decrease of > 3.21 log10CFU/mL).  ANOVA showed that 191 
there was a significant difference between substrates and CFU/mL at 4 hours (MD= 0.08, 95% 192 
CI, 2.5-3.7 log 10 CFU/mL, p= 0.041) (Table 1).  Multiple regression analysis demonstrated that 193 
there was a significant association between CFU/mL with substrate at 4 hours (partial eta 194 
squared [eta] =0.493, p< 0.001) and at 24 hours (eta=0.208, p<0.001).  The overall model fit was 195 
R2 = 0.954. 196 
  197 




Ventilator associated pneumonia, a common nosocomial infection often caused by bacteria that 199 
produce biofilm, results in increased morbidity, medical costs and multi-drug resistant 200 
organisms.(2, 3, 29-32)  In one study, adult patients with VAP were hospitalized longer (38 vs. 201 
13 days, p<0.01), mortality rates were higher (50% vs. 34%, p<0.01), and hospital costs were 202 
greater ($70,568 vs. $21,620, p< 0.01) compared to uninfected ventilated patients, with estimated 203 
VAP attributable costs of $11,897.(32)  However, limited diagnostic criteria and modification of 204 
ETTs make VAP prevention particularly challenging and difficult especially for neonates and 205 
children.(2) 206 
In children, re-intubation and tracheostomy insertion create the additional risk of damaging their 207 
small and fragile airway; therefore, re-intubation or tracheostomy after a standard duration of 208 
intubation is not routinely practiced. Thus, the longer the ETTs remain in patients due to 209 
prolonged mechanical ventilation, the more likely biofilms are to develop and adhere.(33-35)  210 
This bacterial accumulation of biofilms on ETTs may become dislodged during simple routine 211 
care such as suctioning or due to ventilation air flow.  Bacteria and biofilm that break off become 212 
planktonic and seed further in the airway, causing more complicated pneumonia.(8, 36) 213 
 214 
One controversial approach to treatment of VAP is “selective decontamination of the digestive 215 
tract” with broad spectrum intravenous (IV) antimicrobials.(37, 38)  However, IV prophylaxis is 216 
not widely accepted due to fear of creating antibiotic resistant strains among VAP pathogens.  In 217 
the pediatric population, one of the most common VAP pathogen is P. aeruginosa, accounting 218 
for 17-25% of VAP.(2, 4, 5)  Our model is most consistent with the practice of direct instillation 219 
of liquid antimicrobial agents through the ETT as prophylaxis against, or treatment of VAP 220 
caused by P. aeruginosa compared to inhalation of nebulized antibiotics.(39)  Instillation 221 
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treatments pose less risk of systemic toxicity than IV administration because antimicrobial agents 222 
can be delivered locally using ETTs or tracheostomy tubes in children and neonates.  Moreover, 223 
instillation can deliver drug directly to the site of pneumonia whereas nebulized drug may adsorb 224 
on the ETT, permeate into the ETT wall, or remain in the proximal airway. Therefore, our study 225 
model using ETT chips is useful to help understand the effects of tobramycin and polymyxin-E, 226 
alone or in combination, to treat VAP cause by P. aeruginosa.    227 
 228 
In our study, we examined P. aeruginosa growth with or without the presence of medical grade 229 
polyvinyl chloride (PVC) ETT to evaluate the bactericidal effects of two antibiotics in the 230 
condition of VAP.  We found that in an in vitro condition, the bactericidal effect of tobramycin 231 
or polymyxin-E monotherapy required greater than 2 times the MIC at 24 hours for the pre-232 
biofilm condition (prevention).  However, antibiotics demonstrated different activity against the 233 
two different strains.  For PAO1, tobramycin monotherapy was equally active for killing 234 
compared to the combination approach.   For 25668, the combination therapy was more active 235 
for killing compared to monotherapy at 24 hours (Fig 2.a-f); this finding may be related to the 236 
biofilm-forming abilities of each bacterium.   237 
 238 
Our study also demonstrated that two of the antibiotics tested in either monotherapy or in 239 
combination showed inactivity or indifference once biofilm was formed on ETTs against both 240 
Pseudomonas strains (Fig 3.a - f).  This is in contrast to the conclusions drawn by Herrmann et 241 
al. using a 96-peg Calgary biofilm device in vitro showing combination therapy with colistin-242 
tobramycin combination was superior to monotherapy against Pseudomonas biofilm.(40)   243 
 244 
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Many in vitro studies have used commercially available PVC coupons, which have different 245 
texture and flexibility (based on the plasticizer content compared to medical grade PVC ETTs).  246 
We hypothesized that bacterial colonies would form differently on commercially available PVC 247 
coupons compared to medical grade PVC ETTs.  To capture Pseudomonas growth in relation to 248 
different material surfaces more accurately, we studied the same antibiotic therapy against 249 
Pseudomonas PAO1 using both PVC coupon and PVC ETTs.  There was the significant 250 
association among CFU/mL and substrate at 4 and 24 hours (Table 1), thus it showed the 251 
importance of utilizing same device material to mimic VAP condition to evaluate antibiotic 252 
activity on biofilm.   253 
 254 
In conclusion, neither single nor combination therapy with tobramycin and/or polymyxin-E 255 
demonstrated killing activity once Pseudomonas biofilm was already formed on ETTs, however, 256 
no antagonism was noted.  Bactericidal effects against pre-formed biofilm (simulating 257 
prevention) in the presence of ETTs suggest that surveillance cultures could identify pathogens 258 
prior to biofilm formation, and allow prophylactic or targeted approaches to therapy, especially 259 
when Pseudomonas is a potential pathogen.  In addition, this study demonstrated the importance 260 
of material choice in vitro time kill study.  Further investigation could incorporate wild type 261 
strains as well as clinically feasible treatment options for VAP in children.   262 
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Figure 1.a-f. Time Kill against planktonic P. aeruginosa.  Tobramycin against planktonic P. 389 
aeruginosa PAO1 (Fig 1.a), 25668 (Fig 1.b), polymyxin-E against planktonic P. aeruginosa 390 
PAO1 (Fig 1.c), 25668 (Fig 1.d), combination of tobramycin and polymyxin-E against 391 
planktonic P. aeruginosa PAO1 (Fig 1.e) and 25668 (Fig 1.f).  Results are presented as mean ± 392 
standard deviation.  393 
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Figure 2.a-f. Time Kill against pre-biofilm formed P. aeruginosa.  Tobramycin against P. 395 
aeruginosa PAO1 (Fig 2.a), 25668 (Fig 2.b), polymyxin-E against P. aeruginosa PAO1 (Fig 396 
2.c), 25668 (Fig 2.d), combination of tobramycin and polymyxin-E against P. aeruginosa PAO1 397 
(Fig 2.e) and 25668 (Fig 2.f) with presence of ETT chips.  Results are presented as mean ± 398 
standard deviation.   399 
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Figure 3. a-f. Time Kill against biofilm formed P. aeruginosa.  Tobramycin against P. 401 
aeruginosa PAO1 (Fig 3.a), 25668 (Fig 3.b), polymyxin-E against P. aeruginosa PAO1 (Fig 402 
3.c), 25668 (Fig 3.d), combination of tobramycin and polymyxin-E against P. aeruginosa PAO1 403 
(Fig 3.e) and 25668 (Fig 3.f).  Results are presented as mean ± standard deviation.  404 




Table 1: Comparison of log10 colony forming unit/mL (CFU/mL) change at 4 hours from 0 hr 406 
growth control between endotracheal tube (ETT) and polyvinyl chloride (PVC) coupons.   407 
 
Tobramycin Polymyxin-E Tobramycin + Polymyxin-E 
ETT PVC coupon ETT PVC coupon ETT PVC coupon 




-1.77±0.04 -3.36± 0.46 -4.09±0.10 
2 x MIC -3.97 ±0.21 
 
-0.71±0.01 -3.92± 0.03 -2.86±0.10 -3.99±0.10 -4.24±0.03 
4 x MIC -3.97 ±0.21 
 
-1.23±0.03 -3.92±0.03 -3.16±1.2 -3.99±0.10 -4.24±0.03 
8 x MIC -3.97 ±0.21 
 
-1.06±0.03 -3.92±0.03 -3.49±1.28 -3.99±0.10 -4.24±0.03 
Average change ± standard deviation. 408 
